Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice

Hepatology

Volumn 59, Issue 4, 2014, Pages 1381-1392

  Wang, Zhigang ^a,b   Dou, Xiaobing ^a,c   Li, Songtao ^a   Zhang, Ximei ^a   Sun, Xinguo ^d   Zhou, Zhanxiang ^d   Song, Zhenyuan ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; CD36 ANTIGEN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADIPOCYTE; ADIPOSE TISSUE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; UPREGULATION;

ADIPOSE TISSUE; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ETHANOL; HEPATOCYTES; HUMANS; HYPERLIPIDEMIAS; LIVER; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RECEPTORS, LDL; UP-REGULATION;

EID: 84896490894     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26912     Document Type: Article

References (39)

1. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010;51:307-328.
2. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7:408-413.
3. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006;290:G852-858.
4. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002;277:29342-29347.
5. Ji C, Chan C, Kaplowitz N. Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol 2006;45:717-724.
6. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004;127:1798-8084.
7. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003;278:27997-28004.
8. Zhong W, Zhao Y, Tang Y, Wei X, Shi X, Sun W, et al. Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol 2012;180:998-1007.
9. Sugimoto T, Yamashita S, Ishigami M, Sakai N, Hirano K, Tahara M, et al. Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 2002;36:157-162.
10. Hendriks HF, van Haaren MR, Leenen R, Schaafsma G. Moderate alcohol consumption and postprandial plasma lipids in men with different risks for coronary heart disease. Alcohol Clin Exp Res 2001;25:563-570.
11. Van de Wiel A. The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med 2012;862504.
12. Bessembinders K, Wielders J, van de Wiel A. Severe hypertriglyceridemia influenced by alcohol (SHIBA). Alcohol Alcohol 2011;46:113-116.
13. Fielding BA, Reid G, Grady M, Humphreys SM, Evans K, Frayn KN. Ethanol with a mixed meal increases postprandial triacylglycerol but decreases postprandial non-esterified fatty acid concentrations. Br J Nutr 2000;83:597-604.
14. Savolainen MJ, Baraona E, Leo MA, Lieber CS. Pathogenesis of the hypertriglyceridemia at early stages of alcoholic liver injury in the baboon. J Lipid Res 1986;27:1073-1083.
15. Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK. Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptorÇ mRNA. Hum Mol Genet 1994;3:531-537.
16. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, et al. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 1995;270:15747-15754.
17. Yagyu H, Lutz EP, Kako Y, Marks S, Hu Y, Choi SY, et al. Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem 2002;277:10037-10043.
18. Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, et al. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001;21:1488-1493.
19. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, et al. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 2004;45:1475-1481.
20. Tao H, Hajri T. Very low density lipoprotein receptor promotes adipocyte differentiation and mediates the proadipogenic effect of peroxisome proliferator-activated receptor gamma agonists. Biochem Pharmacol 2011;82:1950-1962.
21. Perman JC, Boström P, Lindbom M, Lidberg U, StÅhlman M, Hägg D, et al. The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction. J Clin Invest 2011;121:2625-2640.
22. Oka K, Pastore L, Kim IH, Merched A, Nomura S, Lee HJ, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001;103:1274-1281.
23. Shen GM, Zhao YZ, Chen MT, Zhang FL, Liu XL, Wang Y, et al. Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J 2012;441:675-683.
24. Jo H, Choe SS, Shin KC, Jang H, Lee JH, Seong JK, et al. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. Hepatology 2013;57:1366-1377.
25. Lieber CS, DeCarli LM. Effects of mineral and vitamin supplementation on the alcohol-induced fatty liver and microsomal induction. Alcohol Clin Exp Res 1989;13:142-143.
26. Zhang X, Wang Z, Li J, Gu D, Li S, Shen C, Song Z. Increased 4-hydroxynonenal formation contributes to obesity-related lipolytic activation in adipocytes. PLoS One 2013;8:e70663.
27. Hybertson BM, Gao B, Bose SK, McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 2011;32:234-246.
28. Gong P, Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 2006;43:144-153.
29. Kang L, Chen X, Sebastian BM, Pratt BT, Bederman IR, Alexander JC, et al. Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation. J Biol Chem 2007;282:28465-28473.
30. Diehl AM. Obesity and alcoholic liver disease. Alcohol 2004;34:81-87.
31. Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, et al. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem 2009;284:30049-30057.
32. Pardina E, Baena-Fustegueras JA, Llamas R, Catalán R, Galard R, Lecube A, et al. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg 2009;19:608-616.
33. Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, Darteil R, et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett 2004;566:173-177.
34. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 2009;47:1304-1309.
35. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991;266:11632-11639.
36. Huang J, Tabbi-Anneni I, Gunda V, Wang L. Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism. Am J Physiol Gastrointest Liver Physiol 2010;299:G1211-1221.
37. Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 2012;61:3208-3218.
38. Barajas B, Che N, Yin F, Rowshanrad A, Orozco LD, Gong KW, et al. NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. Arterioscler Thromb Vasc Biol 2011;31:58-66.
39. Iimuro Y, Frankenberg MV, Arteel GE, Bradford BU, Wall CA, Thurman RG. Female rats exhibit greater susceptibility to early alcohol-induced liver injury than males. Am J Physiol 1997;272:G1186-1194.